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Transport of thyroid hormone across the cell membrane is
required for thyroid hormone action and metabolism. We have
investigated the possible transport of iodothyronines by the
human system L amino acid transporter, a protein consisting
of the human 4F2 heavy chain and the human LAT1 light
chain. Xenopus oocytes were injected with the cRNAs coding
for human 4F2 heavy chain and/or human LAT1 light chain,
and after 2 d were incubated at 25 C with 0.01–10 M [125I]T4,
[125I]T3, [
125I]rT3, or [
125I]3,3-diiodothyronine or with 10–100
M [3H]arginine, [3H]leucine, [3H]phenylalanine, [3H]ty-
rosine, or [3H]tryptophan. Injection of human 4F2 heavy chain
cRNA alone stimulated the uptake of leucine and arginine due
to dimerization of human 4F2 heavy chain with an endoge-
nous Xenopus light chain, but did not affect the uptake of
other ligands. Injection of human LAT1 light chain cRNA
alone did not stimulate the uptake of any ligand. Coinjection
of cRNAs for human 4F2 heavy chain and human LAT1 light
chain stimulated the uptake of phenylalanine > tyrosine >
leucine > tryptophan (100 M) and of 3,3-diiodothyronine >
rT3 T3 > T4 (10 nM), which in all cases was Na
 independent.
Saturation analysis provided apparent Michaelis constant
(Km) values of 7.9 M for T4, 0.8 M for T3, 12.5 M for rT3, 7.9
M for 3,3-diiodothyronine, 46 M for leucine, and 19 M for
tryptophan. Uptake of leucine, tyrosine, and tryptophan (10
M) was inhibited by the different iodothyronines (10 M), in
particular T3. Vice versa, uptake of 0.1 M T3 was almost com-
pletely blocked by coincubation with 100 M leucine, trypto-
phan, tyrosine, or phenylalanine.
Our results demonstrate stereospecific Na-independent
transport of iodothyronines by the human heterodimeric sys-
tem L amino acid transporter. (Endocrinology 142: 4339–4348,
2001)
THYROID HORMONE IS essential for the developmentof different organs, in particular the brain, and for the
metabolic control of virtually all tissues throughout life (1–3).
Its major effects include stimulation of oxygen consumption
and thermogenesis; acceleration of carbohydrate, protein,
lipid, and bone mineral turnover; and increased contractility
of skeletal muscles and heart (2, 3). Most actions of thyroid
hormone are initiated by binding of the active form of T3 to
nuclear receptors, which are associated with regulatory el-
ements in the promoter region of target genes (3, 4). Binding
of T3 to its receptor induces the release of corepressors and
the recruitment of coactivators, usually resulting in the stim-
ulation of gene transcription (4).
Although T3 is the receptor-active form of thyroid hor-
mone, its precursor T4 is the predominant product secreted
by the follicular cells of the thyroid gland (5, 6). Although
some T3 is also secreted, most T3 is produced by enzymatic
outer ring deiodination of T4 in peripheral tissues (5, 6). Both
T4 and T3 are inactivated by inner ring deiodination to the
metabolites rT3 and 3,3-diiodothyronine (3,3-T2), respec-
tively (5, 6). The three deiodinases (D1–D3) involved in these
conversions are homologous selenoproteins with different
catalytic profiles, tissue distributions, and physiological
functions (7, 8). D1 in liver and kidney appears important for
systemic T3 production, D2 in tissues such as brain and
pituitary for local T3 production, and D3 in brain and other
tissues for T4 and T3 degradation. All three deiodinases are
transmembrane proteins with their active site exposed to the
cytoplasm (5–8).
The metabolism and action of thyroid hormone are intra-
cellular events requiring the uptake of extracellular hormone
through the plasma membrane. Although iodothyronines
are lipid-soluble compounds, they cannot readily cross the
lipid bilayer of the cell membrane by simple diffusion. This
is because the polar zwitter-ionic alanine side-chain prevents
passage of the iodothyronine molecule through the hydro-
phobic inner part of the cell membrane constituted of the
aliphatic fatty acid chains. Evidence accumulated over the
last two decades indicates that uptake of thyroid hormone in
different tissues is mediated by transporters (6, 9–12). Work
in our laboratory has demonstrated the presence of multiple
iodothyronine transporters in rat and human liver cells (6, 11,
12). Two energy- and Na-dependent transporters appear of
particular importance for hepatic uptake of T4 and rT3, and
of T3, respectively, showing nanomolar affinities for their
ligands, but different dependencies on cellular ATP levels (6,
11, 12). However, iodothyronine transporters in other tissues
show different characteristics. Isolated rat pituitary cells also
show carrier-mediated uptake of different iodothyronines,
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but this appears to be mediated by a single transporter (13).
In contrast, cultured neonatal rat cardiomyocytes show spe-
cific uptake of T3, but not of T4 (14). A variety of cells,
including rat pituitary cells (13), GH-producing tumor cells
(15), erythrocytes (16, 17), cardiomyocytes (14), and astro-
cytes (18); mouse neuroblastoma (19) and thymocytes (20);
and human choriocarcinoma cells (21, 22), show competition
between uptake of iodothyronines and neutral amino acids
such as leucine (Leu) and tryptophan (Trp). This may not be
surprising, because iodothyronines are iodinated amino acid
derivatives built from two tyrosine (Tyr) molecules. Based on
the above observations it has been suggested that thyroid
hormone may be taken up in different tissues at least in part
through system L or system T amino acid transporters
(15–19).
In particular through the pioneering work of Christensen
(23, 24), different classes of amino acid transporters have
been distinguished on the basis of their preference for certain
types of amino acids (e.g. neutral, acidic, or basic), their
specificity for natural or artificial prototypic ligands, as well
as their mechanism of transport (e.g. Na dependent or Na
independent). A rapidly increasing number of amino acid
transporters has been characterized in recent years, includ-
ing the 4F2-related heterodimeric transporters (for reviews,
see Refs. 25–27). The 4F2 or CD98 cell surface antigen has
been known for some time to be expressed in many tissues,
especially on activated lymphocytes and tumor cells, but
only recently has it been identified as a family of amino acid
transporters (25–28). These heterodimeric transporters each
consist of a common 4F2 heavy chain (4F2hc) and a member
of a family of homologous light chains, 7 of which have now
been cloned (25–41). 4F2hc is a glycosylated protein with a
single transmembrane domain, whereas the light chains are
not glycosylated and have 12 putative transmembrane do-
mains; they are linked through a disulfide bond (25–28). One
of the 7 light chains mentioned above appears to dimerize
preferentially with another heavy chain, termed rBAT (for
related to basic amino acid transport), which is homologous
to 4F2hc, suggesting the existence of a superfamily of het-
erodimeric amino acid transporters consisting of multiple
heavy and light chains (25–28, 38–40).
In combination with 4F2hc, two 4F2 light chains mediate
the Na-independent transport of large neutral (branched
chain and aromatic) amino acids such as Leu, Tyr, Trp, and
phenylalanine (Phe). This is typical for the system L amino
acid transporter, hence the names LAT1 and LAT2 for these
light chains (25–27, 29–33). Two other light chains forming
heterodimers with 4F2hc mediate the Na-dependent up-
take of neutral amino acids such as Leu as well as the Na-
independent uptake of basic amino acids such as arginine
(Arg). This is characteristic of the system yL amino acid
transporter, which is why these light chains are named
yLAT1 and yLAT2 (25–27, 34–36). We have tested the
possible involvement of these heterodimeric 4F2 transporters
in the transport of thyroid hormone by studying the uptake
of the iodothyronines T4, T3, rT3, and 3,3-T2 by Xenopus laevis
oocytes injected with cRNA coding for human 4F2hc
(h4F2hc) alone or in combination with cRNA coding for
human LAT1 (hLAT1), mouse LAT2 (mLAT2), hyLAT1, or
hyLAT2. Whereas the system yL transporters did not me-
diate the uptake of iodothyronines, effective thyroid hor-
mone transport was observed with the system L transporters,
in particular the h4F2hc/hLAT1 heterodimer, which is the
subject of this report.
Materials and Methods
Materials
Nonradioactive l-iodothyronines and 3,3,5-triiodothyroacetic acid
(Triac) were obtained from Henning Berlin GmbH & Co. (Berlin, Ger-
many). 3,5-[125I]T4, 3-[
125I]T3, and carrier-free Na
125I were purchased
from Amersham Pharmacia Biotech (Uppsala, Sweden). 3,5-[125I]rT3
and 3,3-[125I]T2 were prepared by radioiodination of 3,3-T2 and
3-monoiodothyronine, respectively, using the chloramine-T method,
followed by purification on Sephadex LH-20 (Amersham Pharmacia
Biotech). [125I]T4 and [
125I]rT3 were also purified on Sephadex LH-20
immediately before use (42). d-T3, Phe, Tyr, and 2-aminobicyclo-(2,2,1)-
heptane-2-carboxylic acid (BCH) were purchased from Sigma (St. Louis,
MO), Arg and Leu were obtained from Merck & Co., Inc. (Darmstadt,
Germany), and Trp and bromosulfophthalein (BSP) were purchased
from Fluka (Buchs, Switzerland). 3H-Labeled Arg, Leu, Phe, Tyr, and Trp
were purchased from Amersham Pharmacia Biotech. All other chemicals
were of reagent grade.
RNA preparation
The plasmids containing cDNA coding for h4F2hc and hLAT1,
pSPORT1-h4F2hc (43) and pcDNA1-E16 (29), were linearized with
HindIII and EcoRV (Roche, Mannheim, Germany), respectively, and
transcribed using the Ampliscribe High Yield T7 RNA transcription
kit (Epicentre, Madison, WI). The cRNAs were capped with the
m7G (5)ppp (5)G cap analog (Epicentre) and stored in sterile water at
80 C.
Oocyte isolation and cRNA injection
Oocytes were prepared as described previously (44). After isolation,
oocytes were sorted on morphological criteria and defolliculated man-
ually. Healthy-looking stage V–VI oocytes were kept at 18 C in modified
Barth’s solution containing 20 IU/ml penicillin and 20 g/ml strepto-
mycin (44). The next day, oocytes were injected with 2.3 ng h4F2hc cRNA
and/or 2.3 ng hLAT1 cRNA in 23 nl water using the Nanoject system
(Drummond Scientific, Broomall, PA). Uninjected oocytes were used as
controls, as similar results were obtained using water-injected oocytes.
Injected and uninjected oocytes were kept for 2 d at 18 C in modified
Barth’s solution.
Uptake
Uptake assays were performed as reported previously (44). Groups
of 8–10 oocytes were incubated for 2–60 min at 25 C with 0.01–10 m
[125I]T4, [
125I]T3, [
125I]rT3, or [
125I]3,3-T2, or with 10–100 m [
3H]Arg,
[3H]Leu, [3H]Phe, [3H]Tyr, or [3H]Trp in 0.1 ml incubation medium [100
mm NaCl or choline chloride (ChCl), 2 mm KCl, 1 mm CaCl2, 1 mm
MgCl2, 10 mm HEPES, and 10 mm Tris, pH 7.5]. After incubation, oocytes
were washed four times with 2.5 ml ice-cold Na-containing incubation
medium containing 0.1% BSA. Oocytes were transferred to new tubes
and counted individually.
Efflux
Oocytes injected with cRNAs coding for h4F2hc and hLAT1 were
incubated in groups of 8–10 for 30 min at 25 C with 10 m [3H]Leu or
0.1 m [125I]T3 or [
125I]T2 in 0.1 ml Ch
-containing incubation medium.
One group of oocytes was processed to determine the total uptake of
each ligand as described above. Efflux of internalized ligand from other
groups of oocytes was analyzed as follows. After removal of the me-
dium, oocytes were rapidly washed with 0.5 ml Ch-containing incu-
bation medium at 25 C and incubated for successive 2-min periods at 25
C with 0.5 ml of the same medium without or with 10 mm unlabeled Leu.
After each interval, medium was rapidly replaced by fresh medium and
counted for radioactivity. Radioactivity still associated with the oocytes
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at the end of the 20-min total efflux period was counted as well. Efflux
was quantified by expressing the cumulative release of radioactivity as
a percentage of that present in the oocytes at the start of the efflux period.
Statistics
Data are presented as the mean  sem. Differences were tested for
statistical significance by t test. Kinetic parameters were determined by
fitting the plot of uptake rate (v) vs. ligand concentration (S) to the
Michaelis-Menten equation: v  Vmax/(1  Km/S), where Vmax is the
maximum uptake rate, and Km is the Michaelis constant.
Results
Initial experiments were carried out to reproduce the in-
duction of amino acid transport in Xenopus oocytes after
injection of cRNAs coding for 4F2-related proteins as re-
ported by others (25–41). Uninjected and water-injected oo-
cytes showed negligible uptake of the basic amino acid Arg
and different neutral amino acids, i.e. the aliphatic amino
acid Leu and the aromatic amino acids Phe, Tyr, and Trp.
Figure 1A shows the effects of injection of 2.3 ng h4F2hc
cRNA alone or together with 2.3 ng hLAT1 cRNA on the
uptake of Leu, Phe, Tyr, Trp, and Arg. Incubations were
performed 2 d after cRNA injection at a ligand concentration
of 50 m using incubation medium containing Na or cho-
line (Ch). Injection of oocytes with cRNA coding for hLAT1
alone did not stimulate transport of the different amino acids
(data not shown). Injection of h4F2hc cRNA alone did not
effect transport of Phe, Tyr, or Trp, but induced Na-
dependent transport of Leu and Na-independent transport
of Arg. This is characteristic for the induction of a yL-type
transporter, which has been documented in different studies
and is explained by the dimerization of exogenous h4F2hc
with an endogenous yLAT-type light chain expressed in
native oocytes (25–30). This assumption is supported by ob-
servations that injection of cRNA coding for hyLAT1 or
hyLAT2 in addition to h4F2hc cRNA further markedly in-
creased Na-dependent transport of Leu and Na-indepen-
dent transport of Arg compared with those in oocytes in-
jected with h4F2hc cRNA alone (data not shown). Coinjection
of oocytes with h4F2hc cRNA and hLAT1 cRNA did not
increase Arg transport above that observed after injection of
h4F2hc cRNA alone. Compared with oocytes injected with
h4F2hc cRNA alone, oocytes injected in addition with hLAT1
cRNA showed a further marked increase in Leu uptake,
which, however, became almost completely Na indepen-
dent. Coinjection of cRNA coding for h4F2hc and hLAT1 also
resulted in a large induction of the transport of Phe and Tyr
and a much smaller increase in the uptake of Trp, which in
all cases was Na independent. This is in agreement with
previous reports, and characteristic for the induction of an
L-type amino acid transporter. Marked stimulation of the
Na-independent uptake of 100 m Leu was also observed
after coinjection of h4F2hc and mLAT2 cRNA (data not
shown).
Figure 1B shows the uptake of 10 m Leu, Tyr, and Trp in
Ch-containing medium by oocytes coinjected with h4F2hc
and hLAT1 cRNA as a function of incubation time. Data were
corrected for transport in uninjected oocytes, which was
significant only for Trp because of the relatively small in-
duction of Trp transport by h4F2hc plus hLAT1 cRNA in-
jection. Trp uptake was linear with time of incubation for at
least 60 min. Transport of Leu and Tyr was much faster than
Trp uptake and was linear with time for only approximately
15 min.
Figure 2A shows the uptake of T4, T3, rT3, or 3,3-T2 by
uninjected oocytes and oocytes injected with cRNA coding
for h4F2hc and hLAT1 after incubation for 1 h with 10 nm
iodothyronine in medium with or without Na. As shown
previously, significant uptake of iodothyronines was ob-
served in uninjected oocytes, which is a major drawback of
this expression system for the cloning of thyroid hormone
transporters. Iodothyronine uptake by native oocytes de-
creased in the order 3,3-T2  T3  T4  rT3 and was some-
what lower in incubation medium containing Ch instead of
Na. Injection of oocytes with h4F2hc cRNA alone or with
hLAT1 cRNA alone did not increase the uptake of any io-
dothyronine (data not shown). The lack of effect of injection
with h4F2hc cRNA alone suggests that the yL-type trans-
porter generated by dimerization of the exogenous heavy
chain with an endogenous light chain does not mediate trans-
port of iodothyronines. This is supported by findings that
coinjection of h4F2hc cRNA and cRNA coding for hyLAT1
or hyLAT2 did not stimulate iodothyronine transport in
oocytes (data not shown). However, injection of oocytes with
both cRNA coding for h4F2hc and hLAT1 resulted in signif-
icant increases in net iodothyronine uptake, which decreased
in the order 3,3-T2 rT3 T3 T4, and in all cases was Na

independent. Smaller increments in iodothyronine uptake
were noted after coinjection of h4F2hc cRNA and mLAT2
cRNA (data not shown).
Figure 2B shows the uptake of 0.1 m T3 and 3,3-T2 in-
duced by injection of oocytes with both h4F2hc and hLAT1
cRNA as a function of time of incubation in Ch-containing
medium. Transport of T3 was linear with time for at least 60
min. Transport of 3,3-T2 was much faster than T3 uptake and
was linear with time for about 45 min.
The saturation kinetics of iodothyronine uptake by the
heterodimeric h4F2hc/hLAT1 transporter were studied by
incubation of oocytes injected with cRNA for both subunits
during 1 h with 0.1–10m ligand in Ch-containing medium.
Iodothyronine uptake through the oocytes’ endogenous
transporter(s) was determined in parallel incubations with
uninjected oocytes. The results are presented in Fig. 3, show-
ing that iodothyronine uptake was saturable in both unin-
jected and cRNA-injected oocytes. Michaelis-Menten analy-
sis of the results obtained with uninjected oocytes provided
apparent Km values of 2–14 m for the different iodothy-
ronines. Iodothyronine transport mediated by the h4F2hc/
hLAT1 transporter was determined by subtraction of the
uptake rates in uninjected oocytes from those observed in
oocytes injected with the cRNAs for both subunits. Michae-
lis-Menten analysis of the corrected data provided apparent
Km values of 7.9 m for T4, 0.8 m for T3, 12.5 m for rT3, and
7.9 m for 3,3-T2. Vmax values were 2.6, 1.1, 11.3, and 28
pmol/oocyteh for T4, T3, rT3, and 3,3-T2, respectively. The
fold stimulation of iodothyronine uptake induced by injec-
tion of oocytes with cRNA for h4F2hc and hLAT1 varied with
increasing ligand concentration (0.1–10 m) from 2.1–2.7 for
T4, from 2.2–1.9 for T3, from 4.4–7.6 for rT3, and from 3.2–13.7
for 3,3-T2. The kinetics of transport of Leu and Trp by the
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h4F2hc/hLAT1 transporter were analyzed similarly using
ligand concentrations of 1–100 m, yielding Km values of 46
m for Leu and 19 m for Trp (data not shown). These data
are in good agreement with previous reports (29–32).
Competition between iodothyronine and amino acid
transport by the heterodimeric h4F2hc/hLAT1 transporter
was studied by testing the effects of 10 m unlabeled iodo-
thyronine on the uptake of 10 m labeled Leu, Tyr, or Trp or
the effects of 100 m unlabeled amino acid on the uptake of
0.1 m labeled T3. Figure 4A demonstrates that uptake of 10
m Leu, Tyr, and Trp by h4F2hc/hLAT1 was inhibited by the
different iodothyronines. The degree of competition was
greatest with T3, in agreement with its low apparent Km
value. Vice versa, uptake of 0.1 m T3 by the h4F2hc/hLAT1
transporter was almost completely inhibited by 100 m Leu,
Trp, Tyr, or Phe, whereas iodothyronine uptake by the en-
dogenous transporter(s) was not affected (Fig. 4B).
The specificity of iodothyronine and amino acid transport
by the h4F2/hLAT1 transporter was further investigated by
testing the effects of the T3 analogs d-T3 and Triac, the organic
anions BSP and taurocholate (TC), and the prototypic L-type
ligand BCH on uptake of l-T3 and l-Leu by the heterodimeric
amino acid transporter (Fig. 5). Uptake was studied in the
absence of Na using 0.1 m [125I]T3 or 10 m [
3H]Leu as
ligands and oocytes injected with cRNA for h4F2hc and
hLAT1 and was corrected for uptake in oocytes injected with
h4F2hc cRNA only. In general, Leu uptake was somewhat
less sensitive to the different competitors than T3 uptake,
perhaps because Leu uptake was tested at a relatively high
ligand concentration. Neither [125I]T3 nor [
3H]Leu uptake
FIG. 1. A, Uptake of amino acids by Xe-
nopus oocytes injected with cRNA cod-
ing for h4F2hc alone (hc) or in combi-
nation with cRNA coding for hLAT1
(hclc). Oocytes were incubated for 60
min at 25 C with 50 M 3H-labeled Leu,
Phe, Tyr, Trp, or Arg in incubation me-
dium containing Na or Ch. Data were
corrected for minor uptake observed in
uninjected oocytes. B, Time course of
uptake of amino acids by oocytes in-
jected with cRNAs coding for h4F2hc
and hLAT1. Oocytes were incubated for
2–60 min with 10 M 3H-labeled Leu
(F), Tyr (Œ), or Trp (f) in Ch-contain-
ing medium. Data were corrected for
minor uptake observed in uninjected oo-
cytes. Data are the mean SEM of 8–10
oocytes. *, P  0.001 vs. corresponding
oocytes injected with h4F2hc cRNA
alone.
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was significantly inhibited by 10m d-T3 or Triac, in contrast
to the potent inhibition by 10m l-T3. Tested at 100m, BCH
produced at least the same marked inhibition of [3H]Leu and
[125I]T3 uptake as Leu itself. The prototypic organic anion
transporter ligand BSP and the bile acid TC had little effect
on uptake of either ligand (Fig. 5).
It has been demonstrated that the h4F2hc/hLAT1 trans-
porter mediates the exchange of intra- and extracellular
amino acids (29, 30). In agreement with these reports, efflux
of labeled Leu taken up by h4F2hc/hLAT1-expressing oo-
cytes was greatly stimulated by the addition of 10 mm un-
labeled Leu to the efflux medium (Fig. 6A). In contrast, 10 mm
extracellular Leu only slightly stimulated the efflux of 3,3-T2
internalized by h4F2hc/hLAT1-expressing oocytes (Fig. 6B),
whereas it did not affect the efflux of T3 taken up by such
oocytes (data not shown).
Discussion
In agreement with previous reports from our laboratory,
uninjected or water-injected oocytes show significant trans-
port of iodothyronines (44–46). Uptake of iodothyronines by
native oocytes is partially Na dependent and is saturated at
increasing ligand concentrations, with apparent Km values of
2–14 m, suggesting the involvement of one or more un-
identified transporters. This endogenous iodothyronine
transport is not inhibited by the addition of large concen-
trations of different amino acids, which suggests that iodo-
thyronines are not taken up by amino acid transporters na-
FIG. 2. A, Uptake of iodothyronines by
uninjected Xenopus oocytes () or oo-
cytes injected with cRNAs coding for
h4F2hc and hLAT1 (hclc). Oocytes
were incubated for 60 min at 25 C with
10 nM 125I-labeled T4, T3, rT3, or 3,3-T2
in incubation medium containing Na
or Ch. B, Time course of uptake of io-
dothyronines by oocytes injected with
cRNAs coding for h4F2hc and hLAT1.
Oocytes were incubated for 2–60 min
with 0.1M 125I-labeled T3 (F) or 3,3-T2
(Œ) in Ch-containing medium. Data
were corrected for uptake observed in
uninjected oocytes. Data are the
mean SEM of 8–10 oocytes. *, P 0.01
vs. corresponding uninjected oocytes.
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tive to the oocytes. This is supported by observations that
uptake of various amino acids by uninjected oocytes is neg-
ligible. However, injection of oocytes with cRNA coding for
h4F2hc results in a marked induction of Na-dependent up-
take of the neutral amino acid Leu and Na-independent
uptake of the basic amino acid Arg. This is in agreement with
previous publications from other laboratories and is ex-
plained by the formation of a functional yL-type transporter
by dimerization of the exogenous h4F2 heavy chain with an
endogenous yLAT-type light chain (25–41). Uptake of io-
dothyronines is not stimulated by the injection of h4F2hc
cRNA alone, indicating that iodothyronines are not trans-
ported by yL-type transporters. This idea is supported by
our findings that coexpression of h4F2hc and either hyLAT1
or hyLAT2 does not induce iodothyronine transport, al-
though the Na-dependent transport of Leu as well as the
Na-independent uptake of Arg are further markedly
increased.
Injection of oocytes with hLAT1 cRNA alone does not
induce the transport of the various amino acids and iodo-
thyronines, indicating that expression of a 4F2-like heavy
chain by native oocytes is negligible. However, if oocytes are
coinjected with cRNA for both h4F2hc and hLAT1, uptake of
the large, neutral amino acids Leu, Phe, Tyr, and Trp, but not
that of the basic amino acid Arg, is markedly stimulated
above that seen after injection of h4F2hc cRNA alone. The
hLAT1-induced increment in amino acid transport is com-
pletely independent of Na, which confirms the character-
istics of the L-type amino acid transporter (23–27). Also,
transport of the different iodothyronines is markedly stim-
ulated by coexpression of h4F2hc and hLAT1, and for all
iodothyronines the induced transport is completely Na in-
dependent. Tested at low ligand concentrations, the rate of
iodothyronine uptake by the h4F2hc/hLAT1 transporter de-
creases in the order 3,3-T2  rT3  T3  T4. This does not
appear to be a simple reflection of the affinity of the different
iodothyronines for the h4F2hc/hLAT1 transporter, as the
apparent Km value is much lower for T3 than for T4, rT3, and
3,3-T2. The apparent Km of 0.8 m for T3 is the lowest value
reported for a ligand of the h4F2hc/hLAT1 transporter (25–
27, 29, 30). Among the different iodothyronines, by far the
highest Vmax value is observed for 3,3-T2.
As iodothyronines and large neutral amino acids are all
ligands for the h4F2hc/hLAT1 transporter, it is not surprising
that they inhibit each other’s transport. Leu uptake is more
strongly inhibited by l-T3 than by l-T4, l-rT3, 3,3-l-T2, d-T3,
and Triac, in keeping with the low Km value for T3 and the
stereospecificity of this L-type amino acid transporter (24–
30). This is reminiscent of the competition between iodothy-
ronine and amino acid uptake in different cell systems re-
ported previously (13–22). Thus, uptake of T4 and T3 by
NB41A3 mouse neuroblastoma cells is stereospecific, satu-
rable (Km: T3, 3 nm; T4, 6 nm), and inhibited by high con-
centrations of Leu and Phe, but not by -aminoisobutyric
acid, a system A transporter-specific ligand (19). Similar
characteristics of iodothyronine uptake were observed in the
Hs683 human glioma cell line (47). Somewhat different re-
sults were reported for T3 uptake by cultured rat astrocytes,
which express both high affinity (L1) and low affinity (L2)
system L transporters (18). Apparent Km values for uptake of
Leu and Trp by the L1 transporter amount to 8–9 m. T3
uptake by these cells is Na independent and saturable, with
an apparent Km of 2–3 m. L1-mediated uptake of Leu and
Trp is competitively inhibited by T3, and T3 uptake is com-
petitively inhibited by Trp, with corresponding Km and Ki
values. However, T3 uptake is not inhibited by up to 30 mm
Leu (18). It is also interesting to mention the characterization
of saturable and stereospecific iodothyronine transport in
GH4C1 rat pituitary tumor cells (15), showing high affinity
for T3 (Km, 0.4 m) and T4, low affinity for rT3 and thyronine,
and strong inhibition by Leu, Phe, Tyr, Trp, and the L-type
transporter-specific ligand BCH. GH4C1 cells also show high
affinity transport of Leu (Km, 17 m), which is potently in-
hibited by T3 (IC50, 2 m), further supporting the involve-
ment of an L-type transporter in T3 (and T4) uptake (15). Also
in cultured rat anterior pituitary cells, uptake of T4 and T3 is
mediated by a common transporter and inhibited by the
aromatic amino acids Phe, Tyr, and Trp (13).
Blondeau and co-workers (16, 17) demonstrated that T3 trans-
port by rat erythrocytes is Na independent, saturable (Km, 0.14
m), and specific (l-T3  d-T3  T4  rT3  thyronine). T3
uptake is competitively inhibited by the aromatic amino acids
Trp, Phe, and Tyr, but not by d-Trp or Leu. They also showed
low affinity uptake of Trp by rat erythrocytes, with an apparent
Km of 558m. Trp uptake is competitively inhibited by Phe, Tyr,
and iodothyronine analogs, with Ki values identical to those for
inhibition of T3 transport. These results suggest the involve-
ment of a T-type, aromatic amino acid-specific transporter in the
uptake of both Trp and T3 (16, 17). Interestingly, T3 uptake is
markedly trans-stimulated by intracellular Trp, although Trp
uptake is trans-inhibited by intracellular T3 (16, 17). Both T3 and
Trp uptake are inhibited by the thiol-blocking reagent N-
ethylmaleimide. A 45-kDa protein was identified by photo-
FIG. 3. Ligand concentration-dependent uptake of iodothyronines by
uninjected Xenopus oocytes (‚) or oocytes injected with cRNAs coding
for h4F2hc and hLAT1 (E). Oocytes were incubated for 60 min with
0.1–10 M 125I-labeled T4, T3, rT3, or 3,3-T2 in Ch
-containing me-
dium. Uptake induced by expression of h4F2hc/hLAT1 was calculated
by subtraction of uptake in uninjected oocytes from that observed in
injected oocytes (f). Curve-fitting was performed using the Michaelis-
Menten equation v  Vmax/(1Km/S). Data are the means of 8–10
oocytes.
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affinity labeling with [125I]T3 that may be a subunit of the T-type
transporter, but this was not further characterized (48).
Competition between iodothyronine and aromatic amino
acid (e.g. Trp) transport has also been demonstrated in other
cells, e.g. JAR human choriocarcinoma cells (21, 22) and neo-
natal rat cardiomyocytes (14), but it has not been established
whether iodothyronine uptake in these cells is indeed
mediated by amino acid transporters. Of special interest
are observations of countertransport of Tyr derivatives by
the system h transporter located in thyroidal lysosomal
membranes (49, 50). Loading of lysosomes with Tyr or
3-(mono)iodotyrosine (MIT) greatly stimulates the influx of
Tyr, MIT, 3,5-diiodotyrosine, Phe, and Leu. Potent compe-
tition by T4 and T3 suggests that iodothyronines are also
countertransported against Tyr derivatives. The apparent Km
value for MIT is 1.5 m, and Tyr, 3,5-diiodotyrosine, T4, and
T3 show similar high affinities. This exchange mechanism
probably plays an important role in thyroid hormone bio-
synthesis, as the iodotyrosines released by lysosomal hydro-
lysis of Tg must be transported to the cytoplasm for deio-
dination, and the iodothyronines to the cell membrane for
secretion (6).
The apparent Km values of T4, T3, Leu, and Trp in the
106–105 m range for the h4F2hc/hLAT1 transporter ex-
pressed in oocytes most closely resemble those reported for
their uptake by rat GH4C1 pituitary tumor cells (15), sup-
porting the involvement of an L-type transporter. They are
also in reasonable agreement with the apparent Km values for
T4, T3, Leu, and Trp uptake by cultured rat astrocytes (18) and
rat erythrocytes (16, 17), but the complete lack of effect of
FIG. 4. A, Effects of iodothyronines on
the uptake of amino acids by oocytes
injected with cRNAs coding for h4F2hc
and hLAT1. Oocytes were incubated for
5 min (Leu, Tyr) or 60 min (Trp) at 25
C with 10 M 3H-labeled Leu, Tyr, or
Trp in the absence or presence of 10 M
T4, T3, rT3, or 3,3-T2 in Ch
-containing
medium. Data were corrected for minor
amino acid uptake in uninjected oo-
cytes. B, Effects of amino acids on the
uptake of T3 by uninjected Xenopus oo-
cytes () or oocytes injected with cRNAs
coding for h4F2hc and hLAT1 (hclc).
Oocytes were incubated for 60 min at 25
C with 0.1 M [125I]T3 in the absence or
presence of 100M Leu, Trp, Tyr, or Phe
in Ch-containing medium. Data are
the mean  SEM of 8–10 oocytes. *, P 
0.01 vs. incubation without competitor.
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102 m Leu on iodothyronine uptake by these cells suggests
that an aromatic amino acid-specific (T-type) transporter is
involved. Also, the much lower Km values reported for T4
and T3 uptake by the NB41A3 mouse neuroblastoma cells
appear to implicate another (sub)type of amino acid trans-
porter than 4F2hc/LAT1.
The L-type amino acid transporter mediates not only in-
flux, but also efflux, of amino acids. Our results show that the
release of intracellular Leu is stimulated by exchange with
extracellular Leu in agreement with previous reports (29, 30).
Extracellular Leu only induces a small increase in the release
of 3,3-T2 from the oocytes and no release of internalized T3,
which may be explained by strong binding of iodothyronines
to intracellular sites in oocytes.
The above-mentioned properties of the thyroidal lysoso-
mal system h transporter, mediating the exchange of amino
acids such as Leu, Tyr, iodotyrosines, and iodothyronines,
suggest that it may actually be an L-type amino acid trans-
porter. This is also supported by evidence that the high
uptake of radioiodine-labeled MIT and 3-iodo--methylty-
rosine by different tumors is mediated by an L-type trans-
porter (51–53). This principle is used in nuclear medicine for
the scintigraphic visualization of such tumors. If the h4F2hc/
hLAT1 and/or h4F2hc/hLAT2 transporters are indeed re-
sponsible for tumor uptake of the radioactive Tyr deriva-
tives, then the availability of cell systems overexpressing
these transporters would greatly facilitate the development
of improved tumor-seeking radiopharmaceuticals.
Obviously, all cells require amino acid transporters, but,
in contrast to the ubiquitous expression of the 4F2 heavy
chain, the LAT1 and, in particular, LAT2 light chains show
restricted tissue distributions; neither of them is expressed
in liver (25–33). This suggests the existence of other light
chains as yet to be identified, which are involved in the
uptake of aromatic amino acids in tissues that do not
express LAT1 or LAT2. Presumably, one of these consti-
tutes with 4F2hc a T-type transporter specific for aromatic
amino acids, including iodothyronines (16 –18). Perhaps,
additional light chains exist that associate specifically with
the homologous rBAT heavy chain (28), generating trans-
porters that also accept iodothyronines. However, cellular
uptake of iodothyronines is not only mediated by amino
acid transporters. We and others have demonstrated re-
cently that iodothyronines are also transported into liver
by Na-dependent and Naindependent organic anion
transporters, although various members of the Na-
independent organic anion transporter family are also ex-
pressed in other tissues, in particular kidney and brain (46,
54 –58). Typical ligands for these organic anion transport-
ers, BSP and TC, have no effect on iodothyronine uptake
by the h4F2hc/hLAT1 transporter, in contrast to the potent
inhibition by the L-type ligand BCH. However, the major,
Na-dependent hepatic transporters for T4 and T3 remain
to be identified. Iodothyronine uptake by uninjected
oocytes is saturable (apparent Km, 2–14 m), suggesting
that it is carrier mediated. The lack of effect of high con-
centrations of different amino acids on iodothyronine
uptake by native oocytes argues against the involvement
of an amino acid transporter. The type of endogenous
iodothyronine transporter(s) in Xenopus oocytes remains
to be determined.
In summary, we have demonstrated that h4F2hc/hLAT1
and, albeit less effectively, also h4F2hc/mLAT2 are capa-
ble of transporting iodothyronines, in agreement with pre-
vious suggestions that thyroid hormone is taken up in
different tissues via L-type amino acid transporters. Our
findings are in agreement with a recent report published
after completion of our study, showing iodothyronine
transport by the heterodimeric transporter composed of
h4F2hc and the IU12 light chain from Xenopus, which is
homologous to hLAT1 (59). One of the questions that re-
mains to be clarified is the extent to which cellular uptake
of iodothyronines through 4F2-related transporters is
stimulated by countertransport of different intracellular
amino acids. Of course, these transporters may also me-
diate cellular efflux of iodothyronines.
FIG. 5. Effects of various compounds
on the uptake of T3 and Leu by the
h4F2hc/hLAT1 transporter. Oocytes
were injected with h4F2hc cRNA alone
or together with hLAT1 cRNA, and af-
ter 2 d were incubated for 60 min with
0.1 M [125I]T3 or for 5 min with 10 M
[3H]Leu in Chmedium without or with
10M L-T3, D-T3, or Triac or 100M Leu,
BCH, BSP, or TC. Uptake by h4F2hc
cRNA-injected oocytes was subtracted
from uptake by h4F2hc and hLAT1
cRNA-injected oocytes. Net uptake in
the presence of competitor was ex-
pressed as a percentage of control net
uptake in the absence of competitor.
Data are the mean  SEM of 8–10 oo-
cytes. *, P  0.01 vs. control.
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